The first human trials of a new Ebola vaccine developed in just eight weeks by Oxford University scientists are set to begin in the UK, after a deadly outbreak of the virus in the Democratic Republic of Congo (DRC) killed 625 people and infected nearly 1,800.
The vaccine, which uses the same technology as the Oxford-AstraZeneca Covid vaccine credited with saving millions of lives worldwide, targets the Bundibugyo strain of Ebola — a strain for which there is currently no approved vaccine or treatment. The speed of development has been described as extraordinary, but the rigorous safety tests have not been cut short, with teams working around the clock and in parallel.
“Oxford University's new Ebola vaccine, developed in eight weeks, enters UK human trials after DRC outbreak killed 625.”
The first safety trial will take place in Britain, before testing begins in Africa, the region most affected by the virus. The announcement comes as the DRC grapples with one of the worst Ebola outbreaks in recent years, with no existing protection against the specific strain that is spreading.
Oxford University’s new vaccine was developed rapidly after the outbreak was declared, demonstrating how British science can respond with urgency and skill to save lives far beyond the country’s shores. The same technology platform that produced the Covid vaccine is now being turned against Ebola, offering hope in a region where medical resources are stretched.
The upcoming UK trials are a critical first step toward potential widespread use, but they also raise questions about how quickly a vaccine can be deployed to those who need it most. If successful, this could mark a major breakthrough in the fight against a disease that has repeatedly defied containment efforts.
